The good, the bad and the ugly - novel synoptic variables in the personalisation of colon cancer treatment
International Journal of Colorectal Disease · 18.11.2026
DOI: 10.1007/s00384-026-05265-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, online erschienen am 18.11.2026. Verfasst von Sean Davis und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adelaide University.
Abstract (Originalsprache)
Purpose
Standardised international reporting for colon cancer (CC) provides foundational prognostic data. However, novel histopathological variables—tumour-infiltrating lymphocytes (TILs), tumour budding (TB), and poorly differentiated clusters (PDCs)—offer superior insights into tumour biology. This review evaluates their clinical utility in risk stratification and treatment personalisation for stage I–III CC.
Methods
A comprehensive literature review was conducted to evaluate the prognostic and predictive value of TILs, TB, and PDCs in stage I–III CC.
Results
High TIL density is associated with improved oncological endpoints in stage II–III disease. Crucially, in stage III disease, a high Immunoscore predicts a survival benefit from extending adjuvant chemotherapy from 3 to 6 months, whereas low TIL density in mismatch repair deficient may identify a high-risk patient cohort that is otherwise overlooked. Conversely, high-grade (HG) TB and PDCs are potent independent markers of poor prognosis, outperforming traditional histopathological variables in multiple studies. In stage I disease, HG TB/PDCs significantly elevate the risk of lymph node metastasis, providing a critical metric when considering segmental resection after malignant polyp removal. In the stage II/III cohort, HG TB/PDCs correlate with diminished disease-free and overall survival, with emerging data suggesting these variables may identify phenotypes resistant to standard fluoropyrimidine monotherapy.
Conclusion
TILs, TB, and PDCs provide vital, biology-focused prognostic and predictive data using cost-effective, routinely stained sections of tumour. Incorporating these variables into standard synoptic reporting and clinical guidelines will refine risk stratification and advance precision oncology in CC management.
Förderung
- Adelaide University
Zitieren
APA
Davis, S., Watson, M., Bunjo, Z., Ruszkiewicz, A., Krishnan, T., Sammour, T., & Vather, R. (2026). The good, the bad and the ugly - novel synoptic variables in the personalisation of colon cancer treatment. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-026-05265-w
Vancouver
Davis S, Watson M, Bunjo Z, Ruszkiewicz A, Krishnan T, Sammour T, et al. The good, the bad and the ugly - novel synoptic variables in the personalisation of colon cancer treatment. International Journal of Colorectal Disease. 2026. doi:10.1007/s00384-026-05265-w
BibTeX
@article{Davis2026,
author = {Davis, Sean and Watson, Matthew and Bunjo, Zachary and Ruszkiewicz, Andrew and Krishnan, Tharani and Sammour, Tarik and Vather, Ryash},
title = {The good, the bad and the ugly - novel synoptic variables in the personalisation of colon cancer treatment},
journal = {International Journal of Colorectal Disease},
year = {2026},
doi = {10.1007/s00384-026-05265-w}
}
EUVIMED